02-18 Nestle proposes former SNB chief Thomas Jordan for board of directors RE
02-18 Nestle weighs reducing exposure to ice cream business, Bloomberg News reports RE
02-18 Nestlé weighs reducing exposure to ice cream business - Bloomberg news RE
02-18 Nestle Eyes Former SNB Chair for Board, Shuffles Governing Committees DJ
02-18 UBS Sees Bank of Canada on Hold This Year as Inflation Slows in January MT
02-18 Nestlé proposes Fatima D. Francisco and Thomas Jordan for board election RE
02-18 Nestle : Nestlé proposes Ma. Fatima D. Francisco and Thomas Jordan for election to its Board of Directors; updates its governance practices DJ
02-18 Unnatural Products in Pact With Novartis to Develop Macrocyclic Peptide Therapeutics DJ
02-18 Unnatural Products announces licensing agreement with Novartis to develop macrocyclic peptide therapeutics RE
02-18 Unnatural Products, Novartis sign licensing agreement for cardiovascular program RE
02-18 AlphaValue/Baader Europe Downgrades Nestlé to Reduce, Lifts PT MT
02-18 Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program RE
02-18 Berenberg Keeps Roche at Hold After FY25 Annual Report Review; Price Target Up MT
02-18 Swiss telco Sunrise expects stable 2026 revenue to turn to growth in medium term RE
02-18 Novartis Says Chronic Skin Condition Drug Shows Positive Results in Trial DJ
02-18 RBC Updates Alcon Estimates Ahead of FY25 Earnings; Outperform Rating Kept MT
02-18 Novartis Reports Positive Results from Phase 3 Trial of Chronic Inducible Urticaria Oral Drug MT
02-18 Novartis remibrutinib first therapy to achieve phase III primary endpoint in chronic inducible urticaria (Cindu) RE
02-18 Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU) DJ
02-18 Amrize's Board OKs Up to $1 Billion Share Buyback Program MT
02-18 Amrize Logs Lower FY25 Net Income; Revenue Up MT
02-17 Amrize Q4 Adjusted Earnings Rise, Revenue Falls; 2026 Revenue Outlook Set MT
02-17 Earnings Flash (AMRZ) Amrize Posts Q4 Revenue $2.84B, vs. FactSet Est of $2.92B MT
02-17 Earnings Flash (AMRZ) Amrize Posts Q4 Adjusted EPS $0.62 MT
02-17 Fitch Confirms Holcim's Ratings on Strong Financial Profile MT
No results for this search